BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 18325859)

  • 21. Body Dysmorphic Disorder: Clinical Overview and Relationship to Obsessive-Compulsive Disorder.
    Phillips KA; Kelly MM
    Focus (Am Psychiatr Publ); 2021 Oct; 19(4):413-419. PubMed ID: 35747292
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Body dysmorphic disorder: a guide for primary care physicians.
    Phillips KA; Dufresne RG
    Prim Care; 2002 Mar; 29(1):99-111, vii. PubMed ID: 11856661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Suicidality in Body Dysmorphic Disorder.
    Phillips KA
    Prim psychiatry; 2007 Dec; 14(12):58-66. PubMed ID: 18449358
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Body dysmorphic disorder. A guide for dermatologists and cosmetic surgeons.
    Phillips KA; Dufresne RG
    Am J Clin Dermatol; 2000; 1(4):235-43. PubMed ID: 11702368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Body dysmorphic disorder: recognition and treatment.
    Anderson RC
    Plast Surg Nurs; 2003; 23(3):125-8; quiz 129. PubMed ID: 14666808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Body dysmorphic disorder--a fear of imagined ugliness.
    Jefferys DE; Castle DJ
    Aust Fam Physician; 2003 Sep; 32(9):722-5. PubMed ID: 14524210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A retrospective review of clinical characteristics and treatment response in body dysmorphic disorder versus obsessive-compulsive disorder.
    Saxena S; Winograd A; Dunkin JJ; Maidment K; Rosen R; Vapnik T; Tarlow G; Bystritsky A
    J Clin Psychiatry; 2001 Jan; 62(1):67-72; quiz 73. PubMed ID: 11235937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder.
    Phillips KA; Albertini RS; Rasmussen SA
    Arch Gen Psychiatry; 2002 Apr; 59(4):381-8. PubMed ID: 11926939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Body dysmorphic disorder.
    Castle DJ; Rossell S; Kyrios M
    Psychiatr Clin North Am; 2006 Jun; 29(2):521-38. PubMed ID: 16650721
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of fluvoxamine in body dysmorphic disorder.
    Phillips KA; Dwight MM; McElroy SL
    J Clin Psychiatry; 1998 Apr; 59(4):165-71. PubMed ID: 9590666
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Body dysmorphic disorder: diagnosis and treatment of imagined ugliness.
    Phillips KA
    J Clin Psychiatry; 1996; 57 Suppl 8():61-4; discussion 65. PubMed ID: 8698683
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder.
    Phillips KA; McElroy SL; Dwight MM; Eisen JL; Rasmussen SA
    J Clin Psychiatry; 2001 Feb; 62(2):87-91. PubMed ID: 11247107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Suicidality in body dysmorphic disorder: a prospective study.
    Phillips KA; Menard W
    Am J Psychiatry; 2006 Jul; 163(7):1280-2. PubMed ID: 16816236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Body dysmorphic disorder: Symptoms, prevalence, assessment and treatment].
    Hardardottir H; Hauksdottir A; Bjornsson AS
    Laeknabladid; 2019 Mar; 105(3):125-131. PubMed ID: 30806630
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder.
    Phillips KA
    Am J Psychiatry; 2005 Feb; 162(2):377-9. PubMed ID: 15677604
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Delusional versus nondelusional body dysmorphic disorder: recommendations for DSM-5.
    Phillips KA; Hart AS; Simpson HB; Stein DJ
    CNS Spectr; 2014 Feb; 19(1):10-20. PubMed ID: 23659348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Body dysmorphic disorder--dysmorphophobia].
    Jakubietz M; Jakubietz R; GrĂ¼nert J
    Zentralbl Chir; 2007 Feb; 132(1):38-43. PubMed ID: 17304434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacotherapy of somatoform disorders.
    Fallon BA
    J Psychosom Res; 2004 Apr; 56(4):455-60. PubMed ID: 15094032
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder.
    Phillips KA; Kelly MM
    Int Clin Psychopharmacol; 2009 Jan; 24(1):26-8. PubMed ID: 19060721
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical features of body dysmorphic disorder in adolescents and adults.
    Phillips KA; Didie ER; Menard W; Pagano ME; Fay C; Weisberg RB
    Psychiatry Res; 2006 Mar; 141(3):305-14. PubMed ID: 16499973
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.